Neurogene price target raised to $55 from $49 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Neurogene (NGNE) to $55 from $49 and keeps a Buy rating on the shares. The firm says the low-dose NGN-401 data look impressive and better than TSHA-102. It is “cautiously optimistic “that there is a regulatory and development path forward for low-dose NGN-401.